Lapixen

Lacidipine, the active ingredient in Lapixen, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adults with essential hypertension by selectively inhibiting L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced systemic vascular resistance.

GNH USA supplies Lapixen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution efficiently.

Lacidipine is indicated for the treatment of hypertension, a condition characterized by chronically elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Isolated systolic hypertension: provides blood pressure control in older patients with predominantly elevated systolic pressure.

Lacidipine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially on standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: rapid swelling of face, lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzyme elevations or hepatitis.

When prescribing lacidipine, clinicians should observe several precautionary measures to ensure patient safety.

- Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Liver function: evaluate hepatic enzymes before initiating therapy. - Elderly patients: start at lower dose and monitor for dizziness. - Concomitant antihypertensives: adjust doses to prevent additive effects. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Lacidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma levels, risking hypotension. - Grapefruit juice: can raise drug concentration, leading to excessive blood pressure drop. - Other potent antihypertensives (e.g., beta‑blockers, ACE inhibitors): may cause additive hypotensive effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lacidipine effectiveness. - Digoxin: lacidipine may increase digoxin levels, requiring serum monitoring.